Prohibits manufacture, sale, and prescription of certain monitoring devices in certain drug products that contain monitoring devices.
Impact
If enacted, A4451 would amend existing state law, specifically the New Jersey Consumer Fraud Act, to classify any violation of this prohibition as an unlawful practice. This change would impose significant penalties on businesses and individuals who do not comply, including fines of up to $10,000 for first offenses and up to $20,000 for subsequent offenses. Moreover, it would allow the Attorney General of New Jersey to issue cease and desist orders and enforce punitive damages, thereby enhancing regulatory control over potential infringements.
Summary
Assembly Bill A4451 aims to prohibit the manufacture, sale, distribution, and prescription of certain prescription drug products that incorporate ingestible devices intended for patient monitoring. The bill defines an 'ingestible device' as any type of microchip or ingestible event marker that allows for electronic monitoring of the individual ingesting the drug. This legislative measure stems from concerns over privacy, data protection, and the potential misuse of such monitoring technologies in healthcare.
Contention
The discourse surrounding A4451 highlights various perspectives regarding the use of ingestible devices in medicine. Proponents argue that banning such technologies is essential for safeguarding patient privacy and preventing unauthorized data tracking. Conversely, opponents may raise concerns about limiting technological advancements in healthcare, suggesting that these devices can improve patient adherence and monitoring. The challenge lies in balancing innovative medical solutions with robust privacy protections, a topic likely to lead to ongoing debate in legislative sessions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.